|1.||Kinghorn, A Douglas: 10 articles (02/2015 - 05/2004)|
|2.||Grever, Michael R: 7 articles (02/2015 - 05/2009)|
|3.||Lucas, David M: 7 articles (02/2015 - 05/2009)|
|4.||Pelletier, Jerry: 5 articles (04/2010 - 07/2008)|
|5.||Pan, Li: 4 articles (02/2015 - 09/2011)|
|6.||Lehman, Amy: 4 articles (02/2015 - 05/2009)|
|7.||Zhang, Xiaoli: 4 articles (02/2015 - 05/2009)|
|8.||Su, Bao-Ning: 4 articles (05/2009 - 05/2004)|
|9.||Lozanski, Gerard: 3 articles (02/2015 - 05/2009)|
|10.||Byrd, John C: 3 articles (01/2013 - 05/2009)|
01/01/2013 - "In vivo, an antitumor effect was observed with 0.4 mg/kg silvestrol compared to controls after one week, and survival of tumor-bearing mice was improved with a median survival time of 42 and 28 days in the silvestrol and control groups, respectively. "
07/01/2015 - "A small-molecule inhibitor of the translation factor eIF4A, silvestrol, bypasses the signaling feedbacks, reduces MYC translation, and inhibits tumor growth in a mouse model of colorectal tumorigenesis. "
02/20/2015 - "We show that silvestrol induces direct anti-tumor activity against EBV-transformed lymphoblastoid cell lines (LCL), with growth inhibition, decreased expression of the EBV oncogene latent membrane protein-1, and inhibition of the downstream AKT, STAT1 and STAT3 signaling pathways. "
02/20/2015 - "We utilized in vitro and in vivo models of EBV-LPD to simultaneously examine the impact of silvestrol on both tumor and normal immune function. "
02/20/2015 - "The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease."
|2.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|3.||B-Cell Leukemia (Leukemia, B Cell)
05/07/2009 - "These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias."
09/01/2012 - "The protein synthesis inhibitor silvestrol has potent activity in B-cell leukemias via the mitochondrial pathway of apoptosis, and also reduces cyclin D1 expression in breast cancer and lymphoma cell lines. "
|4.||Prostatic Neoplasms (Prostate Cancer)
09/01/2006 - "The purpose of the current study was to evaluate the mechanism of silvestrol's cytotoxicity in human prostate cancer cells (LNCaP). "
01/01/2009 - "We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis. "
07/01/2007 - "In this study, the mechanism of cytotoxicity mediated by silvestrol in the LNCaP (hormone-dependent human prostate cancer) cell line was investigated. "
01/01/2013 - "Silvestrol in vivo efficacy was investigated using MV4-11 leukemia-engrafted mice. "
05/07/2009 - "We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models. "
05/07/2009 - "In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells. "
05/14/2004 - "Silvestrol (1) was further evaluated in vivo in the hollow fiber test and in the murine P-388 leukemia model."
09/01/2012 - "As showed in other leukemias, silvestrol caused Mcl-1 depletion followed by mitochondrial depolarization and caspase-dependent apoptosis, effects not related to inhibition of CDK4/6. Silvestrol significantly (P < 0.0001) prolonged survival in a MCL xenograft model without detectable toxicity. "
|7.||Eukaryotic Initiation Factor-4E
|9.||RNA Helicases (RNA Helicase)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)